

Launching a new bioceramic product within accelerated timeline

Therapeutic area

- **Trauma**

Product

- **CoLOSSIS™**

Capabilities

- **Biomaterials expertise**
- **Quality assurance & regulatory affairs (QARA) support**
- **Technical support**



Partnering for the challenge

Our partner, a top 10 global medical device manufacturer, needed a biomaterial solution to replace a product removed from the market due to supply chain challenges. The Biomedical team at dsm-firmenich was challenged with scaling up our partner’s manufacturing processes and collaborating effectively to support a commercialized product launch with an accelerated timeline.

Why it matters

The global bone-void-fillers market is expected to be valued at \$4.1 billion by 2026, up from \$2.7 billion in 2020.¹ The growth is due, in part, to the increase in the prevalence of bone-related disorders such as fractures, traumas, bone infections, and bone tumors, and the number of clinical studies supporting the use of bone-void fillers.



Our innovation

To successfully manufacture and launch its new product, our partner leveraged several of our core competencies.

- ✓ Due to the responsiveness and expertise of our technical team, our partner was able to evaluate and introduce an innovative product.
- ✓ Our partner chose CoLOSSIS™ for its unique bioceramic and fast-setting properties.
- ✓ Our established supply chain and robust quality system—which is compliant with applicable ISO and ASTM standards and has MDSAP certification—mitigated commercialization risk and enabled our partner to meet its accelerated timeline.

Our impact

The expertise of the Biomedical team at dsm-firmenich resulted in a successful product launch. To meet demand, manufacturing capacity was doubled, and significant product marketing, technical, and training support were provided during the launch period to drive market adoption and month-over-month revenue growth.